Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 4Active not recruiting 3Unknown 2Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Head & Neck 2Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 39Lung Neoplasms 21Carcinoma, Hepatocellular 18Breast Neoplasms 16Small Cell Lung Carcinoma 14Urinary Bladder Neoplasms 9Squamous Cell Carcinoma of Head and Neck 7Neoplasm Metastasis 7Liver Neoplasms 7Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Ovarian Neoplasms 5Neoplasms 5Endometrial Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Renal Cell 5Carcinoma 5Biliary Tract Neoplasms 5Stomach Neoplasms 4Melanoma 4Colorectal Neoplasms 4Cholangiocarcinoma 4Prostatic Neoplasms 3Neoplasms by Site 3Esophageal Neoplasms 3Carcinoma, Squamous Cell 3Uterine Cervical Neoplasms 2Turcot syndrome 2Thyroid Neoplasms 2Thoracic Neoplasms 2

Interventions

Carboplatin 12Paclitaxel 11pembrolizumab 10Fluorouracil 10Oxaliplatin 9Radiotherapy 7Nivolumab 7Leucovorin 7Cisplatin 6Radiotherapy, Intensity-Modulated 5Magnetic Resonance Spectroscopy 5Taxes 4durvalumab 3Trastuzumab 3Docetaxel 3Capecitabine 3tislelizumab 2relatlimab 2Surgical Procedures, Operative 2Standard of Care 2Specimen Handling 2Radiation 2Proton Therapy 2Practice Guidelines as Topic 2Irinotecan 2Immune Checkpoint Inhibitors 2Fluorodeoxyglucose F18 2Drug Therapy 2Cetuximab 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Esophageal Neoplasms × durvalumab × Clear all
NCT03174275 2026-02-23

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Active not recruiting
39 enrolled 8 charts
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NeoTX Therapeutics Ltd.

Phase 1 Active not recruiting
120 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03653052 2025-04-24

CALIBRATION

Cambridge University Hospitals NHS Foundation Trust

Phase 2 Active not recruiting
18 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡